Axa S.A. Neurocrine Biosciences Inc Transaction History
Axa S.A.
- $32.2 Billion
- Q4 2024
A detailed history of Axa S.A. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Axa S.A. holds 297,704 shares of NBIX stock, worth $32.4 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
297,704
Previous 269,172
10.6%
Holding current value
$32.4 Million
Previous $31 Million
31.13%
% of portfolio
0.13%
Previous 0.1%
Shares
31 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
96.6MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.55 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.1 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$533 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$329 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$277 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.4B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...